Prepared by:
Duke Evidence-based Practice Center
Douglas C. McCrory, M.D., M.H.Sc.
John W. Williams, M.D.
Rowena J. Dolor, M.D., M.H.S.
Rebecca N. Gray, D.Phil.
Jane T. Kolimaga, M.A.
Shelby Reed, Ph.D.
John Sundy, M.D., Ph.D.
David L. Witsell, M.D.
Investigators
File Name Description Software Version File Size ________________________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 2002 51KB 7 pages Contents: Cover, Title Page, Preface, Structured Abstract ________________________________________________________________________________________________ 02conts.doc Microsoft Word® Document MS Word® 2002 26KB 3 pages Contents: Table of Contents ________________________________________________________________________________________________ 03summ.doc Microsoft Word® Document MS Word® 2002 53KB 7 pages Contents: Summary: Overview, Reporting the Evidence, Methodology, Findings, Future Research ________________________________________________________________________________________________ 04chap1.doc Microsoft Word® Document MS Word® 2002 136KB 11 pages Contents: Chapter 1. Introduction: Background, Scope and Purpose, Epidemiology of Allergic Rhinitis, Overview of Disease Biology, Burden of Illness, Management Strategies and Treatment Options, Costs and Work Performance, Treatment Outcomes by Clinician Specialty, Prevalence and Patient Outcomes by Race and Ethnicity, Target Populations, Target Practice Settings, Target Audience, Limitations of the Report; Table 1. 1996 US prevalence rates and numbers for hay fever/allergic rhinitis without asthma by age, sex, race, and family income; Table 2. 1996 US prevalence rates and numbers for hay fever/allergic rhinitis without asthma, by geographic location and place of residence ________________________________________________________________________________________________ 05chap2.doc Microsoft Word® Document MS Word® 2002 267KB 23 pages Contents: Chapter 2. Methodology: Topic Assessment and Refinement, Causal Pathway, Literature Search and Review, Data Abstraction, Grading of Articles (Quality Scoring), Quality Control Procedures; Figure 1. Causal Pathway; Table 3. Search strategy - preliminary general search, MEDLINE®, 1966 through September 2001; Table 4. Search strategy - clinician specialty differences, MEDLINE®, 1966 to October Week 3 2001; Table 5. Search strategy - environmental measures (1), MEDLINE®, 1966 to October Week 1 2001; Table 6. Search strategy - environmental measures (2), MEDLINE®, 1966 to October Week 1 2001; Table 7. Included study designs, by key research question; Table 8. Abstract and full-text screening criteria; Table 9. Summary of results of abstract and full-text screening; Table 10. Full-text screening results, by key research question and by inclusion/exclusion criteria; Table 11. Partial data abstraction - sample; Table 12. Oxford Centre for Evidence-based Medicine levels of evidence (May 2001) ________________________________________________________________________________________________ 06chap3.doc Microsoft Word® Document MS Word® 2002 807KB 55 pages Contents: Chapter 3. Results: Costs and Work Performance, Environmental Measures, Immunotherapy, Combined Treatments, Clinician Specialty Differences, Racial and Ethnic Variation; Figure 2. Meta-analysis of placebo-controlled trials of immunotherapy for seasonal allergic rhinitis; Figure 3. Meta-analysis of trials comparing antihistamine + decongestant combinations versus antihistamine alone: effect size based on differences in total symptom severity; Figure 4. Meta-analysis of trials comparing antihistamine + decongestant combinations versus antihistamine alone: effect size based on differences in nasal symptom severity; Figure 5. Meta-analysis of trials comparing antihistamine + decongestant combinations versus decongestant alone: effect size based on differences in total symptom severity; Figure 6. Meta-analysis of trials comparing antihistamine + decongestant combinations versus decongestant alone: effect size based on differences in nasal symptom severity; Figure 7. Meta-analysis of trials comparing antihistamine + nasal glucocorticoid combinations versus antihistamine alone: effect size based on differences in nasal symptom severity; Figure 8. Meta-analysis of trials comparing antihistamine + nasal glucocorticoid combinations versus nasal glucocorticoid alone: effect size based on differences in nasal symptom severity; Table 13. Summary of types of data reported in studies abstracted in Evidence Table 1; Table 14. Placebo-controlled randomized controlled trials of injection immunotherapy (IT) for seasonal allergic rhinitis, by type of allergen; Table 15. Data abstracted for meta-analysis of placebo-controlled trials of immunotherapy (IT) for seasonal allergic rhinitis; Table 16. Placebo-controlled randomized controlled trials of injection immunotherapy (IT) for perennial allergic rhinitis, by type of allergen; Table 17. Randomized controlled trials comparing combination pharmacotherapy to monotherapy for allergic rhinitis; Table 18. Data abstracted for meta-analysis of combination treatment articles; Table 19. Summary of meta-analysis of randomized controlled trials comparing combination pharmacotherapy to monotherapy for allergic rhinitis ________________________________________________________________________________________________ 07chap4.doc Microsoft Word® Document MS Word® 2002 32KB 3 pages Contents: Chapter 4. Conclusions: Costs and Work Performance, Environmental Measures, Immunotherapy, Combined Treatments, Clinician Specialty Differences, Racial and Ethnic Variation ________________________________________________________________________________________________ 08chap5.doc Microsoft Word® Document MS Word® 2002 31KB 3 pages Contents: Chapter 5. Future Research: Costs and Work Performance, Environmental Measures, Immunotherapy, Combined Treatments, Clinician Specialty Differences, Racial and Ethnic Variation, Need for Improved and More Uniform Trial Reporting ________________________________________________________________________________________________ 09refs.doc Microsoft Word® Document MS Word® 2002 81KB 9 pages Contents: References ________________________________________________________________________________________________ 10etbl1.doc Microsoft Word® Document MS Word® 2002 387KB 35 pages Contents: Evidence Table 1. Costs and Work Performance ________________________________________________________________________________________________ 11etbl2.doc Microsoft Word® Document MS Word® 2002 374KB 30 pages Contents: Evidence Table 2. Environmental Measures ________________________________________________________________________________________________ 12etbl3.doc Microsoft Word® Document MS Word® 2002 826KB 73 pages Contents: Evidence Table 3. Immunotherapy ________________________________________________________________________________________________ 13etbl4.doc Microsoft Word® Document MS Word® 2002 577KB 36 pages Contents: Evidence Table 4. Combined Treatments ________________________________________________________________________________________________ 14etbl5.doc Microsoft Word® Document MS Word® 2002 111KB 7 pages Contents: Evidence Table 5. Provider Specialty ________________________________________________________________________________________________ 15etbl6.doc Microsoft Word® Document MS Word® 2002 76KB 4 pages Contents: Evidence Table 6. Racial and Ethnic Variation ________________________________________________________________________________________________ 16biblio.doc Microsoft Word® Document MS Word® 2002 501KB 69 pages Contents: Bibliography ________________________________________________________________________________________________ 17acros.doc Microsoft Word® Document MS Word® 2002 21KB 2 pages Contents: Appendix: Acronyms and Abbreviations ________________________________________________________________________________________________
AHRQ Publication No. 03-E015
Current as of March 2003
Internet Citation:
Management of Allergic Rhinitis in the Working-Age Population. File Inventory, Evidence Report/Technology Assessment Number 67. AHRQ Publication No. 03-E015, March 2003. Agency for Healthcare Research and Quality, Rockville, M.D.. http://www.ahrq.gov/clinic/rhnwkinv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services